HeXun Biosciences Co., Ltd.
HeXun Biosciences Co., Ltd. engages in the research and development of stem cell drug development and cardiovascular disease treatments in Taiwan. It provides contract manufacturing; commissioned inspection; aseptic filling; and consulting services. The company was founded in 2019 and is based in Taoyuan City, Taiwan.
HeXun Biosciences Co., Ltd. (6986) - Net Assets
Latest net assets as of September 2025: NT$703.77 Million TWD
Based on the latest financial reports, HeXun Biosciences Co., Ltd. (6986) has net assets worth NT$703.77 Million TWD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$792.78 Million) and total liabilities (NT$89.01 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$703.77 Million |
| % of Total Assets | 88.77% |
| Annual Growth Rate | 36.31% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 12.37 |
HeXun Biosciences Co., Ltd. - Net Assets Trend (2020–2024)
This chart illustrates how HeXun Biosciences Co., Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for HeXun Biosciences Co., Ltd. (2020–2024)
The table below shows the annual net assets of HeXun Biosciences Co., Ltd. from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$620.58 Million | +31.10% |
| 2023-12-31 | NT$473.36 Million | +50.34% |
| 2022-12-31 | NT$314.87 Million | +46.62% |
| 2021-12-31 | NT$214.75 Million | +19.48% |
| 2020-12-31 | NT$179.74 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to HeXun Biosciences Co., Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 13253800000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$30.28 Million | 4.88% |
| Common Stock | NT$460.00 Million | 74.12% |
| Other Components | NT$130.30 Million | 21.00% |
| Total Equity | NT$620.58 Million | 100.00% |
HeXun Biosciences Co., Ltd. Competitors by Market Cap
The table below lists competitors of HeXun Biosciences Co., Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hantech Bio-Technology Co., Ltd.
TWO:1294
|
$33.88 Million |
|
Healthcare Integrated Technologies Inc
PINK:HITC
|
$33.88 Million |
|
Q32 Bio Inc
NASDAQ:QTTB
|
$33.88 Million |
|
Metal Sky Star Acquisition Corporation Ordinary shares
NASDAQ:MSSA
|
$33.90 Million |
|
Articore Group Ltd
AU:ATG
|
$33.87 Million |
|
Metacon AB
ST:META
|
$33.87 Million |
|
THINKWARE Corporation
KQ:084730
|
$33.86 Million |
|
Chien Shing Stainless Steel Co Ltd
TW:2025
|
$33.84 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in HeXun Biosciences Co., Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 473,357,000 to 620,580,000, a change of 147,223,000 (31.1%).
- Net income of 147,223,000 contributed positively to equity growth.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$147.22 Million | +23.72% |
| Total Change | NT$- | 31.10% |
Book Value vs Market Value Analysis
This analysis compares HeXun Biosciences Co., Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.07x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 7.80x to 4.07x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | NT$7.04 | NT$54.90 | x |
| 2022-12-31 | NT$8.40 | NT$54.90 | x |
| 2023-12-31 | NT$12.62 | NT$54.90 | x |
| 2024-12-31 | NT$13.48 | NT$54.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently HeXun Biosciences Co., Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 23.72%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 51.40%
- • Asset Turnover: 0.41x
- • Equity Multiplier: 1.14x
- Recent ROE (23.72%) is above the historical average (2.28%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -20.02% | 0.00% | 0.00x | 1.37x | NT$-64.46 Million |
| 2022 | -1.65% | -10.49% | 0.12x | 1.28x | NT$-36.67 Million |
| 2023 | 7.07% | 25.65% | 0.23x | 1.21x | NT$-13.85 Million |
| 2024 | 23.72% | 51.40% | 0.41x | 1.14x | NT$85.17 Million |
Industry Comparison
This section compares HeXun Biosciences Co., Ltd.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,057,086,200
- Average return on equity (ROE) among peers: 8.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| HeXun Biosciences Co., Ltd. (6986) | NT$703.77 Million | -20.02% | 0.13x | $33.87 Million |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |